At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 56 enrolled
Drug / intervention
lacosamide +1 moredrug
Likely dose
lacosamide 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label Trial of Add on Lacosamide Versus High Dose Monotherapy in Patients With a Seizure Disorder
In Brief
A Phase 3 clinical trial evaluating lacosamide and levetiracetam for Epilepsy. Completed, enrolled 56 participants across 1 site.
Detailed Summary
This is a study to determine whether a combination of low dose lacosamide and levetiracetam is more effective than high dose levetiracetam in patients who have failed low dose levetiracetam.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2011
Enrollment StartAug 2011
Primary CompletionFeb 2014
Study CompletionOct 2014
TodayJul 2026
First PostedApr 29, 2011
Enrollment StartAug 1, 2011
Primary CompletionFeb 15, 2014
Study CompletionOct 21, 2014
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 15.2 years ago
Interventions
lacosamidedrug
Lacosamide maximum of 200 mg/day, to be titrated as follows: * Week 1: 50 mg twice a day * Beginning Week 2: 100 mg twice a day.
levetiracetamdrug
Low dose ≤1500 mg/day, High dose \>1500 mg/day